Webcast, Event, or Conference

»Webcast, Event, or Conference
30 04, 2019

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 2019

2019-04-30T13:24:14+00:00

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 2019 PALO ALTO, Calif., April 30, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will participate and present a corporate update at the ChinaBio® Partnering [...]

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 20192019-04-30T13:24:14+00:00
26 03, 2019

Eiger BioPharmaceuticals to Participate in Conferences in April

2019-03-26T13:24:24+00:00

Eiger BioPharmaceuticals to Participate in Conferences in April PALO ALTO, Calif. – March 26, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will present at upcoming investor, scientific, and orphan drug conferences in April. C. Wainwright Global [...]

Eiger BioPharmaceuticals to Participate in Conferences in April2019-03-26T13:24:24+00:00
20 03, 2019

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019

2019-03-20T13:29:54+00:00

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019 PALO ALTO, Calif., March 20, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the [...]

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 20192019-03-20T13:29:54+00:00
13 03, 2019

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019

2019-03-13T14:34:05+00:00

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019 36% Durable Virologic Response at 24 Weeks Post-Treatment PALO ALTO, Calif., March 13, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced a late-breaker [...]

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 20192019-03-13T14:34:05+00:00
11 03, 2019

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit

2019-03-11T15:07:06+00:00

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit PALO ALTO, Calif., March 11, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the Jefferies [...]

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit2019-03-11T15:07:06+00:00
4 02, 2019

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans

2019-02-04T15:27:59+00:00

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans PALO ALTO, Calif., February 4, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced an oral presentation has [...]

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans2019-02-04T15:27:59+00:00
4 12, 2018

Eiger BioPharmaceuticals to Host R&D Day in New York City

2018-12-04T14:51:54+00:00

Eiger BioPharmaceuticals to Host R&D Day in New York City PALO ALTO, Calif., December 4, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced it will host an R&D Day on December 11, 2018 from 12:00 PM to 2:30 PM EST at [...]

Eiger BioPharmaceuticals to Host R&D Day in New York City2018-12-04T14:51:54+00:00
19 11, 2018

Eiger to Participate in Piper Jaffray Healthcare Conference

2018-11-21T11:28:38+00:00

Eiger to Participate in Piper Jaffray Healthcare Conference PALO ALTO, Calif., November 19, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference on November 27 [...]

Eiger to Participate in Piper Jaffray Healthcare Conference2018-11-21T11:28:38+00:00
18 10, 2018

Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference

2018-10-18T17:03:58+00:00

Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference PALO ALTO, Calif., October 18, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the Eiger management team will participate and host 1:1 investor meetings at the BTIG Biotech Conference at the Langham Hotel in New [...]

Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference2018-10-18T17:03:58+00:00
25 09, 2018

Eiger BioPharmaceuticals to Participate in Investor Conferences

2018-09-25T13:50:24+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences PALO ALTO, Calif., September 25, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present at two investor conferences in October in New York City. Cantor Fitzgerald 4th [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences2018-09-25T13:50:24+00:00